Brief: Chimeric Therapeutics Announces FDA Clearance Of IND Application For CHM 2101
31/10/2023 01:06
Oct 31 (Reuters) - Chimeric Therapeutics Ltd CHM.AX :
* ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101
* PHASE 1A CLINICAL TRIAL FOR CHM 2101 TO INITIATE PATIENT
ENROLMENT IN 2024
Source text for Eikon: ID:nASXrXY59
Further company coverage: CHM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial